With another failure of E-selectin antagonist uproleselan on the books, Glycomimetics Inc. signed an acquisition agreement with privately held, solid tumor-focused Crescent Biopharma Inc., and a syndicate of investors has put up $200 million to make the merger possible. The combined firm will operate under Crescent’s name after the deal closes in the second quarter of 2025, subject to shareholders’ go-ahead.
Ngenebio Co. Ltd. launched a precision diagnostic panel called Oncoaccupanel RNA in South Korea Oct. 29 as a test to detect oncogenic fusion genes commonly found in solid tumors.
Kivu Bioscience has closed a $92 million series A financing to advance its topoisomerase I inhibitor-based antibody-drug conjugate (ADC) pipeline into the clinic.
Dewpoint Therapeutics Inc. has nominated its first development candidate, DPTX-3186, an orally administered small-molecule condensate modulator inhibiting the oncogenic function of β-catenin, for the treatment of Wnt-driven cancers.
Researchers from Immunome Inc. and Zentalis Pharmaceuticals Inc. presented preclinical data for IM-1021, a novel tyrosine kinase-like orphan receptor 1 (ROR1)-targeted antibody-drug conjugate with a new topoisomerase 1 (TOP1) linker payload, being developed for the treatment of solid tumors and B-cell malignancies.
Ottimo Pharma Ltd. has emerged from stealth with a focus on developing innovative cancer therapies for solid tumors. The company’s lead program is jankistomig, a PD-1/VEGFR-2 bifunctional antibody.
Cancer Research UK and Kisoji Biotechnology Inc. have signed an agreement to bring Kisoji's naked anti-TROP2 antibody, KJ-103, into a first-in-human trial. KJ-103 is a single domain antibody that binds to a unique epitope on TROP2.
Adcentrx Therapeutics Inc. has received FDA clearance of its IND application for ADRX-0405 for the treatment of select advanced solid tumors. A first-in-human phase Ia/b trial of ADRX-0405 in patients with select advanced solid tumors, including metastatic castration-resistant prostate cancer, will begin enrollment and dosing this quarter.
